TenderlineUK
Procurement Intelligence
Official OCDS
Find a Tender
complete
Official procurement procedure

HLA TISSUE TYPING FOR BONE MARROW VOLUNTEER DONORS PERFORMED BY 3RD PARTY SUPPLIER

Blood-testing reagents
Published value
Not published
Submission deadline Not published
Lots published1
Procurement Executive Summary
AI & Search Synopsis
Generated from official OCDS record
Tenderline Synopsis: NHS Wales Shared Services Partnership-Procurement Services (hosted by Velindre University NHS Trust): "HLA TISSUE TYPING FOR BONE MARROW VOLUNTEER DONORS PERFORMED BY 3RD PARTY SUPPLIER". Published status: complete. Published value: Value not published. 1 published lot. Submission deadline not published. See the official notice for participation instructions.
Contracting AuthorityNHS Wales Shared Services Partnership-Procurement Services (hosted by Velindre University NHS Trust)Scope & CategoriesNot publishedSubmission Window
complete
No deadline published
Submission GatewayDirect notice routeLegal Basis & RegimeStandard procurementEstimated Value (exc. VAT)Not published
Bidder Intelligence · Authority Profile: NHS Wales Shared Services Partnership-Procurement Services (hosted by Velindre University NHS Trust)
Market Analytics
View Authority Profile →
Derived from OCDS awards & bid statistics
Published history for NHS Wales Shared Services Partnership-Procurement Services (hosted by Velindre University NHS Trust). These figures describe retained records, not a forecast of bids or a measure of buyer bias.
Average Price Reduction
Not availableInsufficient comparable data
Requires at least 5 comparable procedures
Competition Density
1.9Bids / Report
66.3% of reports have one bid
Supplier ConcentrationNo estimate
Insufficient attributable awardsNo concentration estimate available
Payment Terms
Check noticePublished terms
Payment obligations depend on the applicable regime and contract. Consult the official documents.
Coverage: 443 active published awards; 365 bid reports (which may be per lot). Supplier values exclude multi-supplier awards, frameworks and DPS, and use GBP only. They are published award values, not payments. Price reduction compares single-lot, single-award, single-supplier GBP procedures with explicitly non-framework/non-DPS status; increases remain in the average. Unpublished data stays unknown. Awarded suppliers are winners, not all bidders.
Procedure terms
Procedure methodNot published
Procurement categoryNot published
Statuscomplete
Framework / DPSNot published
CompetitionNot published
Above thresholdNot published
Legal basisNot published
Tender period startsNot published
Clarification deadlineNot published
Electronic submissionNot published
Submission languagesNot published
Published2 Jul 2024, 13:24 BST
Last source update2 Jul 2024, 13:24 BST
Recurring procurementNot published
ClassificationBlood-testing reagents
Delivery area
OCIDocds-h6vhtk-029a1f
What is being bought
The unrelated bone marrow volunteer donors are recruited at blood session and added to the donor panel, the HLA tissue typing is outsourced to a 3rd party supplier. The Tissue typing is critical to the matching of a donor with a patient and hence the provision of a life-saving stem cell transplant. The service provided is HLA tissue typing for all relevant genetic markers to facilitate a stem cell transplant. The supplier provides CCR5 testing CCR5 testing (mutation called delta 32 that is protective against the common HIV virus strains)
What changed
From the official release history
  1. Official notice release published
    2 Jul 2024, 13:24 BST
  2. Status changed to complete
    10 Mar 2021, 09:16 GMT
  3. Official notice release published
    10 Mar 2021, 09:16 GMT
  4. Buyer information updated
    10 Mar 2021, 09:16 GMT
Lots and requirements (1)
Published by the contracting authority
  • Lot 1 · #1
    Individual lot title not published
    cancelled
    Published valueNot published
    The unrelated bone marrow volunteer donors are recruited at blood session and added to the donor panel, the HLA tissue typing is outsourced to a 3rd party supplier. The Tissue typing is critical to the matching of a donor with a patient and hence the provision of a life-saving stem cell transplant. The service provided is HLA tissue typing for all relevant genetic markers to facilitate a stem cell transplant. The supplier provides CCR5 testing CCR5 testing (mutation called delta 32 that is protective against the common HIV virus strains)
    Contract periodNot published
    EligibilityNot published
    Options / renewalNot published
Timeline
  1. Procedure published
    2 Jul 2024, 13:24 BST
  2. Award active
    Not published · Not published
  3. Contract active
    Signed 9 Mar 2021, 00:00 GMT · £140,000
Commercial outcome and competition
Awards
Histogenetics
Not published · Not published · active
Contracts
Contract
£140,000 · signed 9 Mar 2021, 00:00 GMT · active
Bid statistics
bids: 1 (lot 1)
electronicBids: 1 (lot 1)
foreignBidsFromEU: 0 (lot 1)
foreignBidsFromNonEU: 1 (lot 1)
smeBids: 0 (lot 1)
Buyer and organisations in this procedure

NHS Wales Shared Services Partnership-Procurement Services (hosted by Velindre University NHS Trust)

Contracting authority GB-FTS-109
View buyer profile
  • NHS Wales Shared Services Partnership-Procurement Services (hosted by Velindre University NHS Trust)
    buyer

    4-5 Charnwood Court,, Heol Billingsley, Parc Nantgarw, Cardiff, UK, CF15 7QZ
    +44 1443848585
  • High Court
    reviewBody

    Royal Courts of Justice, The Strand, London, WC2A 2LL
    +44 2079477501
  • Histogenetics
    supplier

    300 Executive Blvd, Ossining/NY, US, 10562
    +001 9147620300
Documents (0)
Official links; attachments are not copied
No data
No linked documents are published
Related procedures (0)
No data
No related procedures published
Planning and rationale
Planning budgetNot published
No-engagement rationaleNot published
Procedure rationaleAs an international stem cell registry the WBMDR has been working hard to maintain the provision of stem cell products to facilitate transplants locally and globally during this COVID-19 pandemic. We have experienced many challenges such as reducing donor exposure, international flight quarantine, grounding of commercial flights, using freight and cargo flight to transport stem cells (HTA full knowledge), transportation of cryopreserved stem cells to name but a few. Unfortunately, reacting to these changes and implementing safe and viable alternative processes has taken up a great deal of time and the fact that we are working with European registries on this tender process, who have themselves experienced the same COVID related issues, has meant that progress has been limited. This is therefore an interim arrangement whilst a re-tendering process is undertaken.